Organization
Syneos Health
13 clinical trials
5 abstracts
Clinical trial
A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety and Immunogenicity of Recombinant Norovirus Hexavalent Vaccine in Healthy Subjects Aged 18-59 YearsStatus: Not yet recruiting, Estimated PCD: 2024-11-01
Abstract
Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Atrium Health, Levine Cancer Institute, Syneos Health,
Clinical trial
A Single Dose, Double-Blind, Two-Period, Crossover, Comparative Pharmacokinetic Study of Three Tocilizumab Products Administered by the Subcutaneous Route to Normal Healthy VolunteersStatus: Completed, Estimated PCD: 2023-05-04
Clinical trial
Phase 1, Single Multiple Dose Escalation Study in a Randomized, Double-blind, Placebo Controlled Design to Investigate Safety, Tolerability, PK and PD of SC Administered SNK-396 in Subjects With Elevated Low-Density Lipoprotein CholesterolStatus: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Randomized Phase I, Double-Blinded, Parallel Comparative Assessment of PK, PD, Safety, and Immunogenicity of BP11 Versus US-Licensed Xolair® and EU Approved-Xolair® Following a Single 150 mg Dose SC Administration in Healthy Male VolunteersStatus: Completed, Estimated PCD: 2023-11-16
Clinical trial
A Phase 1, First-In-Human, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of APB-R3 in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-12-19
Clinical trial
Phase 1, Open-Label, Single-Ascending Dose, Parallel Group Study to Determine the Pharmacokinetics, Safety, and Tolerability of ATRS-2002 Administered Subcutaneously in Healthy Adult MalesStatus: Withdrawn, Estimated PCD: 2023-04-20
Clinical trial
First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy SubjectsStatus: Completed, Estimated PCD: 2022-11-11
Clinical trial
A Single and Multiple-dose Escalation First-in-Human Study Evaluating the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Administered Via Inhalation and IV Infusion in Healthy Subjects and Patients With Mild Asthma.Status: Terminated, Estimated PCD: 2023-03-02
Clinical trial
A Phase I/IB, First-Time-in-Human, Single Centre, Double-Blind, Randomized, Placebo-controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of VB0004 Administered Orally to Healthy Volunteers; and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk.Status: Recruiting, Estimated PCD: 2023-12-16
Clinical trial
A Phase 1, Single-center, Placebo-controlled, Double-blind, Randomized Trial to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of ACH-000029 in Healthy SubjectsStatus: Terminated, Estimated PCD: 2022-11-02
Clinical trial
A First-in-human, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Intravenous Doses of HM201 (Pegylated Human Adrenomedullin) in Healthy Subjects (Adults)Status: Completed, Estimated PCD: 2022-12-19
Clinical trial
A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of APL-1501 ER Capsules Compared to APL-1202 IR Tablets in Healthy VolunteersStatus: Not yet recruiting, Estimated PCD: 2024-08-21
Clinical trial
Open-Label, Single Dose, Parallel Group, Phase 1 Study in Healthy Volunteers Evaluating Safety, Tolerability, Pharmacokinetics, and Immunogenicity AIO-001 Administered by InjectionsStatus: Active (not recruiting), Estimated PCD: 2024-12-20
Abstract
HB-300, a novel arenavirus-based cancer immunotherapy in patients with metastatic castration-resistant prostate cancer.Org: Thompson Cancer Survival Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, City of Hope Comprehensive Cancer Center, Earle A Chiles Research Institute, Cedars-Sinai Cancer,
Abstract
Development of natural language processing (NLP) models for extracting key features from unstructured notes to create real-world data (RWD) assets for clinical research at scale.Org: ConcertAI, Syneos Health, Merck & Co., Inc.,
Abstract
Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.Org: Syneos Health, Morrisville, NC, NC Medical Research, Gurugram, Indiana University – Purdue University Indianapolis,
Abstract
Reporting of patient reported outcomes in randomized clinical trials (RCTs) in non-small cell lung cancer (NSCLC) patients (pts).Org: Syneos Health, Syneos Health France, Syneos Health Portugal, Syneos Health Israel,